Find early tests for Parkinson
- Trial ID
- NCT06846658
- Official Title
- Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
- Goal
- Find early tests for Parkinson
- Status
- RECRUITING
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Study Type
- OBSERVATIONAL
- Enrollment
- 180 participants
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease, Healthy Subjects (HS)
Plain-Language Summary
The goal is to find early biological signs that can distinguish Parkinson's disease, atypical parkinsonisms like multiple system atrophy, and Lewy body dementia from each other and from healthy aging. Researchers collect samples from the olfactory mucosa (the smell-related nasal tissue), blood and urine, then analyze them for molecular biomarkers such as misfolded proteins like alpha-synuclein and other inflammatory or metabolic signatures that might appear early in disease. About 180 people are being enrolled, including adults with PD, MSA, DLB or other neurodegenerative movement disorders, plus healthy volunteers; the public listing does not specify an age limit.
Locations
- Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP), Sesto Fiorentino, FI, Italy
- IRCCS Centro San Giovanni di Dio, Brescia, Italy
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to find early biological signs that can distinguish Parkinson's disease, atypical parkinsonisms like multiple system atrophy, and Lewy body dementia from each other and from healthy aging. Researchers collect samples from the olfactory mucosa (the smell-related nasal tissue), blood and urine, then analyze them for molecular biomarkers such as misfolded proteins like alpha-synuclein and other inflammatory or metabolic signatures that might appear early in disease. About 180 people are being enrolled, including adults with PD, MSA, DLB or other neurodegenerative movement disorders, plus healthy volunteers; the public listing does not specify an age limit.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 6 months.